Revenue Recognition and Contractual Adjustments (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Summary of Contract Assets and Liabilities

The following table summarizes the values of contract assets, capitalized commissions and contract liabilities as of June 30, 2020 and December 31, 2019 (in thousands):


	June 30, 2020		December 31, 2019
Current pharma contract assets ⁽¹⁾	$	1,255	$	1,000
Long-term pharma contract assets ⁽²⁾	221		153
Total pharma contract assets	$	1,476	$	1,153


Current pharma capitalized commissions ⁽¹⁾	$	183	$	133
Long-term pharma capitalized commissions ⁽²⁾	820		798
Total pharma capitalized commissions	$	1,003	$	931


Current pharma contract liabilities	$	3,570	$	1,610
Long-term pharma contract liabilities ⁽³⁾	631		1,171
Total pharma contract liabilities	$	4,201	$	2,781

⁽¹⁾ Current pharma contract assets and Current pharma capitalized commissions are classified as “Other current assets” on the Consolidated Balance Sheets.

⁽²⁾ Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as “Other assets” on the Consolidated Balance Sheets.

(3) Long-term pharma contract liabilities are classified as “Other long-term liabilities” on the Consolidated Balance Sheets.

Summary of Disaggregation of Revenue

The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):


	Three Months Ended June 30,						Six Months Ended June 30,
	2020		2019		2020		2019
Clinical Services:
Client direct billing	$	45,244	$	54,008	$	99,535	$	103,243
Commercial Insurance	15,148		20,894		37,142		41,802
Medicare and Medicaid	13,541		13,719		30,024		29,581
Self-Pay	(49)		361		165		566
Total Clinical Services	$	73,884	$	88,982	$	166,866	$	175,192
Pharma Services:	13,093		12,731		26,141		22,098
Total Revenue	$	86,977	$	101,713	$	193,007	$	197,290